Echinocandins
Lipopeptide antifungals
Also Caspofungin, Micafungin, Anidulafungin, Rezafungin, Cancidas, Mycamine
- Evidence
- AStrong human evidence
- FDA status
- FDA approvedas of 2026-10-26
- Route
- Intravenous
- Studies cited
- 2 human0 animal or cell
They are hospital drugs given through a vein for serious yeast infections in the blood. Trials of 224 and 245 patients showed they work at least as well as older drugs, with fewer side effects than amphotericin B.
Sold for
Echinocandins are hospital antifungals, not wellness products; the interest is clinical, as the preferred first drugs for bloodstream Candida infections.
Studies say
Randomized trials showed each echinocandin at least as effective as amphotericin B or fluconazole with fewer toxic effects than amphotericin B, which is an A for invasive candidiasis.
Why grade A. Each echinocandin was approved on randomized, double-blind trials against an established antifungal. The two cited here are caspofungin versus amphotericin B in 224 patients with invasive candidiasis and anidulafungin versus fluconazole in 245 patients with invasive candidiasis, 89% of them candidemia only. Rezafungin was approved in 2023 on a noninferiority trial against caspofungin. 123
FDA. Approved. Four echinocandins are FDA-approved antifungals: caspofungin (Cancidas, 2001), micafungin (Mycamine, 2005), anidulafungin (Eraxis, 2006) and rezafungin (Rezzayo, 2023). Their indications center on candidemia, invasive and esophageal candidiasis, with caspofungin also approved for empiric therapy in febrile neutropenia and for aspergillosis refractory to other drugs, and micafungin for prophylaxis in stem-cell transplant recipients. 123
Written from 3 cited sources. Fact-checked 2026-10-27: 16 claims checked, 4 corrected. Last refreshed 2026-10-27. Not physician reviewed.
What this means for you
- What people take it for
- Serious yeast infections
- Can a US doctor prescribe it?
- Yes, FDA approved for serious yeast infections such as Candida in the blood.
- Properly tested in people?
- Yes, in large controlled trials of 224 and 245 patients.
Evidence checklist
- Randomised controlled trial Double-blind vs amphotericin B, fluconazoleyes
- Human study over 100 people 224 and 245 patient trialsyes
- More than one research group Several drugs, trials, and sponsorsyes
- Clinical outcomes, not surrogate markers Treatment success, mortality measuredyes
- Human safety data beyond case reports Well tolerated in trial and label datayes
Drawn from the cited studies below. A dash means the sources give no information.
What it is
Echinocandins are cyclic lipopeptides. Each has a ring of six amino acids and a fatty side chain. They began as fungal products. Chemists then modified them. Caspofungin, micafungin and anidulafungin were approved from 2001 to 2006. Rezafungin lasts longer than anidulafungin, which it is made from. It was approved in March 2023 for candidemia and invasive candidiasis. Its label covers adults and children 12 and older. They must have few or no other options. All of these drugs go into a vein. The gut does not absorb them. 123
They are the only antifungal class that attacks the fungal cell wall. The others hit the cell membrane. That is why echinocandins work against Candida strains resistant to fluconazole. It is also why they cause few of the side effects linked to amphotericin B. 12
How it works
Echinocandins block beta-1,3-D-glucan synthase. This enzyme makes the glucan polymer that forms the backbone of the fungal cell wall. Human cells have no cell wall and no glucan synthase. So the target is specific to fungi. Against Candida species, the drugs kill the fungus. Against Aspergillus, they stunt growth at the tips of the fungal threads but do not kill it outright. That is why caspofungin is approved for aspergillosis only as a salvage treatment. 12
What human research shows
The 2002 trial that established the class randomized 224 adults with invasive candidiasis. They got caspofungin or conventional amphotericin B. Success rates were similar: 73% against 62% in the modified intention-to-treat analysis. Caspofungin did at least as well as the older drug. Death rates did not differ. Amphotericin B caused far more drug-related side effects, including kidney injury and infusion reactions. More patients stopped it. 1
In 2007, researchers compared anidulafungin with fluconazole in 245 patients with candidemia or invasive candidiasis. Treatment worked in 76% of anidulafungin patients and 60% of fluconazole patients. That gap was significant, so the drug looked better. The analysis found no center effect. But when the largest-enrolling site was removed, the rates were 73% and 61%, and the gap was no longer significant. The trial itself concluded only that the drug did at least as well. So the finding reads as 'at least as good as fluconazole, possibly better'. 2
Rezafungin won approval in 2023. A trial showed it did at least as well as caspofungin in candidemia and invasive candidiasis. It stays in the body a long time. So patients get it weekly into a vein, not daily. 3
| Study | Model | Finding |
|---|---|---|
| Mora-Duarte 2002 | Humans, n=224, randomized double-blind, caspofungin vs amphotericin B, invasive candidiasis | Caspofungin was noninferior for clinical success and caused far fewer drug-related adverse events. 1 |
| Reboli 2007 | Humans, n=245, randomized double-blind, anidulafungin vs fluconazole, invasive candidiasis (mostly candidemia) | Success in 76% versus 60%; the difference lost significance when the largest-enrolling site was excluded, and the stated conclusion was noninferiority. 2 |
| Rezzayo prescribing information | FDA label, rezafungin, 2023 | Approved for candidemia and invasive candidiasis in adults and children 12 and older with limited alternatives, based on noninferiority to caspofungin. 3 |
Safety
Patients tolerate echinocandins well. In the caspofungin trial, far fewer patients had to stop the drug than with amphotericin B. Common effects across the class are fever, vein irritation at the infusion site, headache and nausea. Liver enzymes can rise briefly. Fast infusion can cause histamine-type reactions such as flushing and rash. Micafungin's label notes liver tumors in rats at high exposure. No such signal has appeared in humans. 123
Resistance has emerged in Candida glabrata and Candida auris. It comes mainly from mutations in the FKS genes, which code for the target enzyme. It is the main long-term concern for the class. 23
Questions for your clinician
- Which echinocandin fits my infection, and why that one?
- How long will the infusions continue, and what will be monitored?
- Do my liver tests change which antifungal is chosen?
Questions people ask
Are echinocandins FDA-approved?
Yes. Caspofungin, micafungin, anidulafungin and rezafungin are all approved, chiefly for candidemia and invasive candidiasis. Caspofungin has added approved uses: treatment of suspected fungal infection in febrile neutropenia, and salvage treatment of aspergillosis. Micafungin is also approved to prevent infection in stem-cell transplant. 123
Why are echinocandins preferred over fluconazole for candidemia?
They kill Candida and keep working against most fluconazole-resistant strains. In the 2007 anidulafungin trial, they did at least as well as fluconazole, and possibly better. 2
Are echinocandins peptides?
They are cyclic lipopeptides, a ring of six amino acids with a fatty tail. The peptide ring is why you cannot take them by mouth. Stomach acid and gut enzymes would destroy them. 1
What is different about rezafungin?
It is a chemically stabilized form of anidulafungin with a much longer half-life. That allows weekly dosing into a vein instead of daily dosing. It was approved in 2023. Its label covers patients 12 and older with few treatment options. 3